Travere director receives new stock and option grants

Travere Therapeutics, Inc. director Timothy Coughlin reported receiving equity compensation consisting of common shares and stock options.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. director Timothy Coughlin reported receiving equity compensation consisting of common shares and stock options. On May 19, 2026, he was granted 4,000 shares of Common Stock, increasing his direct holdings to 56,250 shares. He was also granted stock options for 12,000 shares of Common Stock at an exercise price of $42.26 per share, exercisable starting May 19, 2027 and expiring on May 19, 2036. The filing notes these are automatic equity grants under Travere’s 2018 Equity Incentive Plan for non-employee director compensation, with the equity award vesting over one year.

Insider Trade Summary

Grant/Award: 16,000 shares

Grant/Award 2 txns

Insider Coughlin Timothy

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	12,000	$0.00	$0.00
Grant/Award	Common Stock	4,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 12,000 contracts (Direct); Common Stock — 56,250 shares (Direct)

Footnotes (2)

1. F1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
2. F2. The equity award vests over a one year period.

Key Figures

Common shares granted: 4,000 shares Options granted: 12,000 options Option exercise price: $42.26 per share +3 more

6 metrics

Common shares granted 4,000 shares Equity grant on May 19, 2026

Options granted 12,000 options Stock option (right to buy) on May 19, 2026

Option exercise price $42.26 per share Stock option strike price

Shares owned after grant 56,250 shares Total direct holdings following transaction

Option exercisability date May 19, 2027 Start of option exercise period

Option expiration date May 19, 2036 End of option exercise period

Key Terms

non-employee director compensation program, 2018 Equity Incentive Plan, Stock option (right to buy), Common Stock

4 terms

non-employee director compensation program financial

"pursuant to the non-employee director compensation program."

2018 Equity Incentive Plan financial

"Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended"

Stock option (right to buy) financial

"security_title: "Stock option (right to buy)""

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Travere Therapeutics (TVTX) director Timothy Coughlin report on this Form 4?

He reported receiving equity compensation, including common shares and stock options. The filing shows automatic grants under Travere’s 2018 Equity Incentive Plan as part of the non-employee director compensation program, rather than open-market purchases or sales of stock.

How many Travere Therapeutics (TVTX) shares did Timothy Coughlin receive in this grant?

He received a grant of 4,000 shares of Travere Therapeutics Common Stock. After this equity award, the filing reports that his total direct ownership increased to 56,250 common shares, reflecting his updated post-grant share position as a non-employee director.

What stock options were granted to Timothy Coughlin by Travere Therapeutics (TVTX)?

He was granted stock options covering 12,000 shares of Travere Therapeutics Common Stock. These options have an exercise price of $42.26 per share, with an exercise start date of May 19, 2027 and an expiration date of May 19, 2036, according to the Form 4.

Is Timothy Coughlin’s Travere Therapeutics (TVTX) equity grant an open-market stock purchase?

No, the Form 4 describes an automatic equity grant, not an open-market purchase. The shares and options were awarded under Travere’s 2018 Equity Incentive Plan as part of the non-employee director compensation program, with the equity award vesting over a one-year period.

When do Timothy Coughlin’s Travere Therapeutics (TVTX) stock options vest and become exercisable?

The filing states the equity award vests over one year, and the options become exercisable starting May 19, 2027. The options then remain outstanding until their stated expiration on May 19, 2036, giving a defined exercise window for the director.

How many Travere Therapeutics (TVTX) shares does Timothy Coughlin hold after this Form 4 transaction?

After the reported grant, Timothy Coughlin directly holds 56,250 shares of Travere Therapeutics Common Stock. This figure reflects his updated ownership position following the 4,000-share equity award disclosed as part of the company’s non-employee director compensation program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coughlin Timothy

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		A		4,000(1)(2)	A	$0	56,250	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$42.26	05/19/2026		A		12,000(1)		05/19/2027(2)	05/19/2036	Common Stock	12,000	$0	12,000	D

Explanation of Responses:

1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

2. The equity award vests over a one year period.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)